Engineering the Future of Cellular Therapeutics
BioModifying Inc. is a pioneering, clinical-stage biopharmaceutical organization dedicated to transforming disease intervention. By developing advanced biomodulatory therapeutics, gene correction systems, and synthetic cellular platforms, we aim to intercept pathological processes at their core molecular origin. Our proprietary methodologies in CRISPR gene editing and CAR-NK cellular therapies provide unprecedented precision in treating oncology and complex metabolic disorders. We are dedicated to providing people-first, helpful solutions that target the actual root causes of chronic genetic and oncological conditions.
Transforming Patient Outcomes Through Genomic Interception
The landscape of modern medicine is rapidly shifting from temporary symptom management to permanent structural genomic correction. BioModifying stands at the forefront of this revolution. We deploy highly targeted, tissue-specific delivery mechanisms that ensure therapeutic payloads reach exact localized environments—such as the hepatocyte matrix or the hematopoietic compartment. This localized targeting significantly reduces the immunogenic footprint and minimizes systemic toxicity, providing a safer, more effective standard of care for patients suffering from refractory solid tumors or rare genetic anomalies.
By bridging the gap between computational biology and clinical practice, our multidisciplinary teams of scientists and clinicians are aggressively advancing multiple investigational assets. Whether it is through the precise deployment of mRNA transcription modulators that instruct host cells to synthesize therapeutic proteins in vivo, or the robust engineering of natural killer cells to penetrate the hostile microenvironment of vascularized sarcomas, our mission remains clear: absolute interception and reversal of disease states.
Our Core Scientific Platforms
In Vivo Gene Editing (CRISPR-Cas24)
Our custom CRISPR systems use high-fidelity, dual-cleavage enzymes to selectively silence or correct mutations in hepatocytes and hematopoietic tissues. By utilizing tissue-specific lipid nanoparticles (LNPs), we achieve targeted delivery with minimal off-target activity. This precision allows us to tackle complex hereditary conditions at the DNA level, permanently restoring normal cellular function without the need for lifelong treatments.
mRNA Transcription Modulation
We design synthetic mRNA molecules optimized for high translation efficiency and low immunogenic profiles. These transcripts instruct patient cells to produce therapeutic enzymes, cytokines, or neutralizing antibodies directly within target organs. Our proprietary lipid formulations stabilize the mRNA during systemic circulation, ensuring maximum uptake and robust intracellular expression precisely where it is needed.
CAR-NK Solid Tumor Interception
By engineering natural killer (NK) cells derived from cord blood with chimeric antigen receptors (CAR), we have developed "off-the-shelf" cellular therapies capable of penetrating and destroying vascularized glioblastomas and sarcomas. Unlike traditional CAR-T approaches, our allogeneic CAR-NK cells do not require patient-specific matching, thereby vastly accelerating the time from diagnosis to therapeutic intervention.
Clinical Development Pipeline
Our investigational therapeutic assets target severe, underserved indications in oncology, immunology, and metabolic genetics, progressing rapidly through early-stage safety trials into rigorous efficacy validations.
| Asset ID | Target Indication | Platform / Mechanism | Current Status |
|---|---|---|---|
| BM-102 | Glioblastoma Multiforme | CAR-NK Cellular Therapy | Phase Ib Clinical Trials |
| BM-205 | Transthyretin Amyloidosis | In Vivo CRISPR Silencing (LNP) | Pre-clinical Testing |
| BM-312 | Refractory Rheumatoid Arthritis | Anti-inflammatory mRNA Vector | Phase IIa Clinical Trials |
| BM-408 | Hereditary Angioedema | mRNA Transcript Translation | IND-Enabling Phase |
Frequently Asked Questions (FAQ)
What is CRISPR-Cas24 in vivo gene editing?
CRISPR-Cas24 is a custom, high-fidelity gene editing system developed by BioModifying that utilizes dual-cleavage enzymes to selectively silence or correct mutations. It is primarily delivered via tissue-specific lipid nanoparticles (LNPs) to treat metabolic and genetic diseases, providing permanent resolution to previously incurable conditions.
How do CAR-NK cellular therapies target solid tumors?
CAR-NK cellular therapies involve engineering natural killer (NK) cells derived from cord blood with chimeric antigen receptors (CAR). These "off-the-shelf" therapeutics are capable of penetrating vascularized solid tumors, such as glioblastomas, to initiate cancer cell destruction without the systemic delays associated with autologous cell harvesting.
What indications are currently in BioModifying's clinical pipeline?
Our current clinical pipeline targets severe indications including Glioblastoma Multiforme (Phase Ib), Transthyretin Amyloidosis (Pre-clinical), Refractory Rheumatoid Arthritis (Phase IIa), and Hereditary Angioedema (IND-Enabling Phase). We are continually expanding our pipeline to address pressing unmet medical needs across various modalities.